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1.1. Introduction
Ulcerative colitis is a lifelong disease arising from an interaction
between genetic and environmental factors, observed predom-
inantly in the developed countries of the world. The precise
aetiology is unknown and therefore medical therapy to cure the
disease is not yet available. Within Europe there is a North–
South gradient, but the incidence appears to have increased in
Southern and Eastern countries in recent years.1,2 Patients may
live with a considerable symptom burden despite medical
treatment (66% describe interference with work and 73% with
leisure activities3) in the hope that the aetiology of ulcerative
colitis will shortly be revealed and a cure emerge. Although this
is conceivable in the next decade, clinicians have to advise
patients on the basis of information available today. Despite
randomised trials there will always be many questions that can
only be answered by the exercise of judgement and opinion.
This leads to differences in practice between clinicians, which
may be brought into sharp relief by differences in emphasis
between countries.
This Consensus endeavours to address these differences.
The Consensus is not meant to supersede the guidelines of
different countries (such as those from the UK,4 or Germany,5)
which reach broadly the same conclusions since they are, after
all, based on the same evidence. Rather, the aim of the
Consensus is to promote a European perspective on the
management of ulcerative colitis (UC) and its dilemmas.
Since the development of guidelines is an expensive and
time-consuming process, it may help to avoid duplication of
effort in the future. A European Consensus is also considered
important because an increasing number of therapeutic trials
recruit from Central and Eastern European countries where
practice guidelines have yet to be published.
This document updates the previous European Consensus
on the diagnosis and management of UC, and was finalised
by the European Crohn's and Colitis Organisation (ECCO) at a
meeting held in Dublin in February 2011. ECCO is a forum for
specialists in inflammatory bowel disease from 31 European
countries. Like the initial Consensus on the diagnosis and
management of ulcerative colitis,6–8 this updated Consensus is
grouped into three parts: definitions and diagnosis; current
management; and management of special situations. This first
section concerns aims, methods and definitions of the Consen-
sus, as well as classification, diagnosis, imaging and pathology
of UC. The second section on Current Management includes
treatment of active disease, maintenance of medically-induced
remission and surgery of UC. The third section on Special
Situations includes ileoanal pouch disorders, cancer surveil-
lance, psychosomatics and extraintestinal manifestations.
Previously included chapters on pregnancy and pediatrics are
no longer included in this guideline, as specific ECCO
Consensus Guidelines on Reproduction and Pregnancy and
Pediatric UC (together with ESPGHAN) cover these topics
extensively.9–11 Alternative therapies are now covered inSection 2 under management of active disease and mainte-
nance therapy of UC. Attention is also drawn to other ECCO
Consensus Guidelines on small bowel endoscopy,12 oppor-
tunistic infections,13 and forthcoming guidelines on Surgery,
Imaging, Endoscopy, Pathology and the management of
anaemia in inflammatory bowel disease (www.ecco-ibd.eu).
The strategy to reach the Consensus involved five steps:1. For the development of the first ECCO guideline pub-
lished in 2008,6–8 relevant questions on each of 14
separate topics concerning diagnosis and treatment of
UC were devised by the Chairs and their working parties.
The questions were focused on current practice and areas
of controversy. Participants were asked to answer the
questions based on their experience as well as evidence
from the literature (Delphi procedure).14 For this update,
an open call for participants was made (see acknowl-
edgements and www.ecco-ibd). Participants were select-
ed by the Guidelines' Committee of ECCO (GuiCom) on the
basis of their publication record and a personal state-
ment. Working parties were established who reviewed
the Consensus statements published in 20086–8 and
recommended whether they required revision, based
upon advances in the published literature. There was an
agreement that there was neither a need for extensive
revision of the histopathology section, nor of the section
on pregnancy and pediatric UC which will not be included
in future UC guidelines, in view of the specific ECCO
Consensus Guidelines which serves as a reference for
these areas.9,10
2. In parallel, the working parties performed a systematic
literature search of their topic with the appropriate key
words using Medline/Pubmed and the Cochrane data-
base, as well as their own files. The evidence level (EL)
was graded (Table 1.1) according to the Oxford Centre
for Evidence Based Medicine.15
3. Revised statements on their topic were then written by
the Chairs, based on answers from their working party, as
well as the literature evidence and were circulated first
among their working party and then among all partici-
pants.
4. All working parties met in Dublin in February 2011 to
agree the statements. Participants gathered under the
Chairmanship of A. Dignass and G. Van Assche to agree
the final version of each statement. Technically this was
done by projecting the statements and revising them on
screen until a consensus was reached. Consensus was
defined as agreement by N80% of participants, termed a
Consensus Statement and numbered for convenience in
the document. Each recommendation was graded (RG)
according to the Oxford Centre for Evidence Based
Medicine,15 based on the level of evidence (Table 1.1).
5. The final document on each topic was written by the
Chairs in conjunction with their working party. Consensus
statements in bold are followed by comments on the
evidence and opinion. Statements are intended to be
Table 1.1 Levels of evidence and grades of recommendation based on the Oxford Centre for Evidence Based Medicine (for details
see http://www.cebm.net/levels_of_evidence.asp#refs). a
Level Diagnostic study Therapeutic study
1a Systematic review (SR) with homogeneity of Level 1 diagnostic
studies
Systematic review (SR) with homogeneity of
randomised controlled trials (RCTs)
1b Validating cohort study with good reference standards Individual RCT (with narrow Confidence Interval)
1c Specificity is so high that a positive result rules in the diagnosis
(“SpPin”) or sensitivity is so high that a negative result rules out
the diagnosis (“SnNout”)
All or none
2a SR with homogeneity of Level N2 diagnostic studies SR (with homogeneity ) of cohort studies
2b Exploratory cohort study with good reference standards Individual cohort study (including low quality RCT;
e.g., b80% follow-up)
2c “Outcomes” Research; Ecological studies
3a SR with homogeneity of 3b and better studies SR with homogeneity of case–control studies
3b Non-consecutive study; or without consistently applied reference
standards
Individual case–control study
4 Case–control study, poor or non-independent reference standard Case-series (and poor quality cohort and case–control
studies )
5 Expert opinion without explicit critical appraisal, or based on
physiology, bench research or “first principles”
Expert opinion without explicit critical appraisal, or
based on physiology, bench research or “first
principles”
Grades of recommendation
A Consistent level 1 studies
B Consistent level 2 or 3 studies or extrapolations from level 1 studies
C Level 4 studies or extrapolations from level 2 or 3 studies
D Level 5 evidence or troublingly inconsistent or inconclusive studies of any level
a CfEBM definitions have been updated in 2011 after the consensus meeting, but the previous CfEBM version from March 2009 was used for
this Consensus.
Table 1.2 Distribution of ulcerative colitis (from16).
Term Distribution Description
E1 Proctitis involvement limited to the rectum
(ie proximal extent of inflammation is
distal to the rectosigmoid junction)
E2 Left-sided involvement limited to the proportion of
the colon distal to the splenic flexure
(analogous to ‘distal’ colitis)
E3 Extensive involvement extends proximal to the
splenic flexure, including pancolitis
968 A. Dignass et al.read in context with qualifying comments and not read in
isolation. The final text was edited for consistency of
style by A. Dignass, G. Van Assche and J. O. Lindsay
before being circulated and approved by the partici-
pants. In some areas the level of evidence is generally
low, which reflects the paucity of randomised controlled
trials. Consequently expert opinion is included where
appropriate.
1.2. Definitions
Common agreement has been reached by ECCO about
frequently used terms. While the significance of some terms
(such as ‘early-’ or ‘pattern of relapse’) are undetermined,
such terms reflect clinical decision-making (such as when to
start immunomodulators) and are considered helpful as a
consequence. The arbitrariness of some of the definitions is
recognised, but the Consensus considers it useful to agree the
terminology.
Ulcerative colitis (UC) is a chronic inflammatory condi-
tion causing continuous mucosal inflammation of the
colon without granulomas on biopsy, affecting the rectum
and a variable extent of the colon in continuity, which is
characterised by a relapsing and remitting course.16
IBD unclassified (IBDU) is the term best suited for the
minority of cases where a definitive distinction between
UC, Crohn's disease, or other cause of colitis cannot
be made after the history, endoscopic appearances,histopathology of multiple mucosal biopsies and appro-
priate radiology have been taken into account.16,17.
Indeterminate colitis is a term reserved for pathologists
to describe a colectomy specimen which has overlapping
features of ulcerative colitis and Crohn's disease.17,18 It
has distinct prognostic factors related to further surgery.
1.2.1. Distribution of disease
The Consensus favours use of the Montréal classification
(Table 1.216) for defining the distribution of disease. This is
used to describe the maximal, macroscopic extent of disease
at colonoscopy, since in the past the extent of disease as
defined by barium enema has been used as a predictor for
the long-term prognosis of UC. The implications of more
9692nd European evidence-based consensus on the diagnosis/management of ulcerative colitis.extensive microscopic disease are still not understood. The
poor correlation betweenmacroscopic andmicroscopic extent
of disease (kappa=0.39) is recognised.17 This is also valid for
an extent-based classification, when the extent varies over
time, underlining the dynamic nature of inflammatory bowel
disease.191.2.2. Disease onset
There is some evidence to suggest that patients with UC
stratified by age (A1: b16; A2:16–40 and A3: N40 years)
have different outcomes. Patients diagnosed before the age
of 16 had a more aggressive initial course, while older age at
diagnosis was found to be associated with a lower risk of
colectomy.20,21 There is also some evidence that UC diagnosed
in the very young has a different aetiology and prognosis. This
is taken into consideration by the paediatric modification to
the Montréal classification.221.2.3. Active disease
For the purposes of this Consensus, clinical disease activity is
grouped into remission, mild, moderate and severe. This refers
to biological activity and not to treatment-responsiveness (see
Section 1.2.8). Precise definitions of disease activity are
appropriate, since confusion arises if the terms are used to
refer only to the least, intermediate or most severe third of
cases that the physician can recall at the time. Among 2006
Consensus participants, 31/59 considered Truelove and Witts'
criteria useful in clinical practice (summarised in Table 1.323),
in conjunction with sigmoidoscopy to confirm active colitis.
The term severe colitis (or ‘acute severe colitis’) is
preferred to ‘fulminant’ colitis, because the term ‘fulminant’
is ill-defined. It was coined in 1950 when it referred to a single
attack going on to death within 1 year,26 which no longer has
relevance today. Severe colitis as defined according to
Truelove and Witts' criteria (Table 1.3 and Section 5.1) is
easy to apply in outpatients, mandates hospital admission for
intensive treatment and defines an outcome (only 70% respond
to intensive therapy). These criteria are recommended for
identifying acute severe colitis by The American College of
Gastroenterology (ACG)27 and the Association of Coloproctology








b4 4 or more if ≥6 and
Pulse b90 bpm ≤90 bpm N90 bpm or
Temperature b37.5 °C ≤37.8 °C N37.8 °C or
Haemoglobin N11.5 g/dL ≥10.5 g/dL b10.5 g/dL or
ESR b20 mm/h ≤30 mm/h N30 mm/h or
or CRP Normal ≤30 mg/L N30 mg/L
The value of the different indices for the purpose of clinical trials is
beyond the scope of the Consensus, but has been reviewed
elsewhere.25 ECCO recognises the need to validate clinical and
endoscopic scoring systems.Moderate colitis has become necessary to distinguish
from mildly active disease, because the efficacy of some
treatments may differ (Section 5). The simplest clinical
measure to distinguish moderate from mildly active colitis is
the presence of mucosal friability (bleeding on light contact
with the rectal mucosa at sigmoidoscopy). The technique of
assessing mucosal friability at flexible sigmoidoscopy has
yet to be standardised. One approach is to apply sufficient
pressure on the mucosa with closed biopsy forceps to create
a dimple, maintain the pressure for 3 s and then define
friability if bleeding occurs from the pressure point. This has
yet to be validated. For review of the various activity indices
see D'Haens et al.25
Wide variation in endoscopic interpretation of disease
activity is recognised (Section 3.6.1).
1.2.4. Remission
Remission is defined as complete resolution of symptoms and
endoscopic mucosal healing (Section 2.2.4). Combining
clinical and endoscopic indices is appropriate for clinical
trials,25,29 but reported remission rates vary by as much as
two-fold depending on the definition of remission used in the
trial.30 In clinical practice, participants agreed that ‘remis-
sion’ meant a stool frequency ≤3/day with no bleeding and
no urgency. Remission defined by individual patients has an
86% sensitivity and 76% specificity for a regulatory-defined
remission (absence of visible blood and absent mucosal
friability), indicating that sigmoidoscopy to confirm mucosal
healing is generally unnecessary in practice.31
1.2.5. Response
Response is defined as clinical and endoscopic improvement,
depending (for the purpose of clinical trials) on the activity
index used. In general, this means a decrease in the activity
index of N30%, plus a decrease in the rectal bleeding and
endoscopy subscores, but there are many permutations.25
1.2.6. Relapse
The term relapse is used to define a flare of symptoms in a
patient with established UC who is in clinical remission,
either spontaneously or after medical treatment. In the
Consensus, 47/59 considered rectal bleeding an essential
component of relapse, and 29/59 believed that a combina-
tion of rectal bleeding with an increase in stool frequency
and abnormal mucosa at sigmoidoscopy was necessary to
define relapse. In clinical trials, the criteria for relapse
should be predefined with the score that is being used for an
individual study.25
1.2.7. Early relapse
An arbitrary, but clinically relevant period of b3 months
after achieving remission on previous therapy defines early
relapse. The therapeutic significance needs to be defined.
1.2.8. Pattern of relapse
Relapsemay be infrequent (≤1/year), frequent (≥2 relapses/
year), or continuous (persistent symptoms of active UC
without a period of remission).32 Although the terms are
arbitrary, they are considered clinically relevant. An alterna-
tive approach that defines disease activity over a 5 year
period has been proposed (Section 2.1.1), but this seems more
relevant to epidemiological studies, since what matters for
970 A. Dignass et al.everyday practice is what is likely to happen in the next year.
The prognostic significance needs to be determined. Never-
theless, care should be taken to distinguish between terms
that describe disease activity at a point in time and those that
describe the longitudinal pattern (or ‘behaviour’) of the
disease (Sections 1.2.3 and 2.2.1). The term ‘chronic active
disease’ has been used in the past to define a patient who is
dependent on, refractory to, or intolerant of steroids, or who
has disease activity despite immunomodulators. Since this
term is ambiguous it is best avoided. Instead, arbitrary, but
more precise definitions are preferred, including steroid-
refractory or steroid-dependence.
1.2.9. Steroid-refractory colitis
Patients who have active disease despite prednisolone up to
0.75 mg/kg/day over a period of 4 weeks. The definition is
consistent with the definition for steroid-refractory Crohn's
disease,33 however, it is likely to evolve, with a reduction in
the duration of steroid therapy as the threshold for biologic
therapy changes.
1.2.10. Steroid-dependent colitis
Patients who are either
i) unable to reduce steroids below the equivalent of prednis-
olone 10 mg/day within 3 months of starting steroids,
without recurrent active disease, or
ii) who have a relapse within 3 months of stopping steroids.
This is consistent with the definition for steroid-dependent
Crohn's disease,33 although an alternative definition of relapse
within 30 days of completing a course of steroids, or steroids
at a dose of 15–25 mg/day for at least 6 months has been
proposed.23 As with steroid-refractoriness, the definition is
likely to evolve as the threshold for biologic therapy changes.
The ECCO definition of steroid-dependence requires that
the total duration of steroids does not exceed 3 months
before a threshold equivalent to prednisolone 10 mg/day is
reached. Patients are still considered steroid-dependent if
they relapse within 3 months of stopping steroids. Although
these limits are arbitrary, they serve as guidance for clinical
practice and may be used for uniformity in clinical trials. The
aim should be to withdraw steroids completely.
1.2.11. Immunomodulator-refractory colitis
Patients who have active disease or relapse in spite of
thiopurines at an appropriate dose for at least 3 months
(i.e. azathioprine 2–2.5 mg/kg/day or mercaptopurine 1–
1.5 mg/kg/day in the absence of leucopenia). The defini-
tion is arbitrary, but has increasing clinical relevance when
deciding on the place of biological therapy or surgery.
1.2.12. Refractory distal colitis
Defined as persistent symptoms due to colonic inflammation
confined to the rectum (proctitis), or left-side of the colon,
despite treatment with oral plus topical steroids and 5ASA
for 4–8 weeks. This represents a common clinical dilemma,
although whether it is a separate entity is unclear.
1.2.13. New patient
A patient with active UC presenting at, or shortly after
diagnosis, with no previous therapy for UC.1.2.14. Alternative therapy
Therapy that is used in place of conventional medicine.
1.2.15. Complementary therapies
Treatments used alongside conventional medicine.
1.2.16. Expert opinion
The term ‘expert’ is used here to refer to the opinion of the
specialists in inflammatory bowel disease representing multi-
ple disciplines from 31 European countries who contributed to
the ECCO Consensus. In some sections opinions from individual
members of other expert bodies were obtained, including
individuals of the European Society of Pathology (ESP) working
group on Digestive Diseases, the European Society of Gastro-
intestinal and Abdominal Radiology (ESGAR) and the European
Society of Paediatric Gastroenterology Hepatology and Nutri-
tion (ESPGHAN).
2. Classification
2.1. Classification according to disease extent
ECCO statement 2A
The extent of ulcerative colitis influences the patient's
management. Disease extent influences the treatment
modality and determines if oral and/or topical therapy
is initiated [EL1b, RG B]. Disease extent influences start
and frequency of surveillance [EL2, RG B]. Therefore, a
classification according to extent of disease is recom-
mended [EL5, RG D]
The preferred classification is an endoscopic classification
as outlined in the Montréal classification into ulcerative
proctitis (limited to the rectum), left-sided colitis (up to
the splenic flexure) and extensive colitis, and by maximal
extent upon follow up [EL5, RG D]
There are several reasons why patients with UC should be
classified according to disease extent. First, the extent of
inflammation will influence the patient's management and
the choice of delivery system for a given therapy. For
instance, topical therapy in the form of suppositories (for
proctitis) or enemas (for left-sided colitis) is often the first
line choice, but oral therapy - often combined with topical
therapy is appropriate for extensive colitis [EL1b, RG B].
Second, the extent of colitis influences the start and the
frequency of surveillance [EL2, RG B]. In the population-
based study from Sweden,34 extent of disease was one of the
risk factors for development of colorectal cancer in 3117 UC
patients followed up from 1 to 60 years after diagnosis. No
increased relative risk (RR) was attributed to disease confined
to the rectum, whereas, the RR for left-sided colitis and ex-
tensive colitis (previously called pancolitis) were 2.8 (95%CI
1.6–4.4) and 14.8 (95%CI 11.4–18.9) respectively. Therefore,
patients with left-sided and extensive colitis are generally
advised to have surveillance colonoscopy, but patients with
proctitis do not need surveillance (Section 2.2). The contribu-
tion of disease extent at diagnosis to the risk of malignancy has
been confirmed more recently by the EC-IBD study group.31
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tion is based on endoscopy and divides disease into proctitis,
left-sided colitis and extensive colitis (beyond the splenic
flexure), as defined by the Montréal Working Group on the
Molecular classification of IBD16,17 (Section 1.1, Table 1.2).
2.2. Classification according to disease severity
ECCO statement 2B
Classification of ulcerative colitis based on disease
severity is useful for clinical practice and dictates the
patient's management [EL1b,RG B]. Disease severity
influences the treatment modality and determines if
no, oral, intravenous or surgical therapy is initiated.
Indices of disease severity have not been adequately
validated. Clinical, laboratory, imaging and endoscopic
parameters, including histopathology assist physicians
in patients' management [EL 2, RG B]. There is no fully
validated definition of remission. The best way of
defining remission is a combination of clinical param-
eters (i.e. stool frequency ≤3/day with no bleeding)
and a normal mucosa at endoscopy [EL5, RG D]. Absence
of an acute inflammatory infiltrate at histology is helpful
2.2.1. Activity and pattern of disease
In a population-based study from Copenhagen County, Langholz
et al. showed that approximately 50% of patients will be in
clinical remission at any time during a given year.35 However,
the cumulative probability of a relapsing course after 25 years
of follow up amounted to 90%. Disease activity in the first
2 years after diagnosis indicated (with 70-80% probability) an
increased probability of 5 consecutive years of active disease
andwas therefore judged to be a good parameter to predict the
future pattern of disease.
Microscopic involvement seems to be of importance as well.
In patients with quiescent UC, a chronic inflammatory cell
infiltrate was present in all biopsy specimens, and crypt
architectural irregularities in two thirds. Fifty two percent of
patients with an acute inflammatory cell infiltrate relapsed
after 12 months of follow-up, whereas only 25% relapsed in the
absence of such an infiltrate (p=0.02). Similarly, relapse
rates were higher in the presence of crypt abscesses, mucin
depletion, and breaches in the surface epithelium.36 The
degree of bowel inflammation is also a risk factor forTable 1.4 Mayo score24,25 and www.gastrojournal.org for full de
Mayo index 0 1
Stool frequency Normal 1–2/dayNno
Rectal bleeding None Streaks
Mucosa Normal Mild friability
Physician's global assessment Normal Mild
The Montréal classification (Table 1.5)16,17 is largely based on Truelovcolorectal cancer in patients with long-standing extensive
UC.37
A distinction should be made between disease activity at
a point in time (remission, mild, moderate, severe) and the
response of disease to treatment (using terms such as 5-ASA
or steroid responsive, steroid refractory, biologic depen-
dent, etc.). The two should not be confused by inappropri-
ate terminology that describes mildly active disease that is
steroid-dependent as ‘severe’. The consequences (biologic
therapy, colectomy) may indeed be considered ‘severe’, but
disease activity remains mild.
2.2.2. Choice of index
A classification of UC based on disease activity and severity is
important because it influences patient management. The
severity of the inflammation will determine if no therapy, oral
therapy, intravenous or surgical therapy is initiated in a given
patient. Many disease activity indices or criteria have been
proposed (see Section 1.2.3 and reference25 for a review), but
none have been adequately validated. The Consensus recog-
nises the need for validated clinical and endoscopic indices that
relate to outcome or treatment decisions. Although modifica-
tions of the original Truelove and Witts' criteria (Section 1.2.3,
Table 1.3) are used in daily practice, the modified Mayo score
(Section 1.2.3, Table 1.4) is used more frequently in current
clinical trials.23 For clinical practice, the Consensus group
judged that a combination of clinical features, laboratory
findings, imaging modalities and endoscopic parameters, in-
cluding histopathology will all assist physicians in their patients'
management. Endoscopic scoring is illustrated in Section 3.5
and Table 3.1.
2.2.3. Clinical and laboratory markers of severity
Among objective clinical features, bloody stool frequency, body
temperature and heart rate are good predictors of outcome.
Laboratory markers have been studied intensively with varying
degrees of success. The widely used acute phase C-reactive
protein is a less good marker for assessing disease activity in UC
than Crohn's disease, except for acute severe colitis, where it
has established value in both adults and children.38–40 A raised
CRP N45 mg/L on day 3 following hospital admission for
severe colitis together with 3–8 stools a day is highly
predictive for colectomy (Section 1.2.5). Other positive
(erythrocyte sedimentation rate, serum procalcitonin41) or
negative (albumin) acute phase proteins have been stud-
ied, but none have demonstrated clear superiority (for
review see42). More recently, faecal markers have demon-
strated promising results. The most studied markers are faecal
calprotectin and lactoferrin, but elastase and the more recent
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ESR N30 mm/h
972 A. Dignass et al.inflammation.43–47 Recent studies emphasise the value of
calprotectin as a tool for diagnosis and the assessment of
disease severity (correlating with endoscopic indices, relapse
and response to treatment).48–51 It must be stressed however
that none of thesemarkers are specific for UC, since theymostly
represent colonic inflammation with an influx of neutrophils
into the gut mucosa, with subsequent shedding of cytoplasmic
granules into the gut lumen.2.2.4. Remission
As with the definition of disease activity, there has also not
been a fully validated definition of remission. The Consensus
group agreed that the best way of defining remission is a
combination of clinical parameters (stool frequency ≤3/day
with no bleeding) and normal or quiescent mucosa at
endoscopy.302.3. Classification according to age at onset or
concomitant primary sclerosing cholangitis
ECCO statement 2C
A classification of UC according to age at onset is of
value [EL2; RG B]. Classification of UC according to the
concomitant presence of PSC is important because it
influences patients' management (surveillance) [EL2;
RG C]A classification according to age at onset is of value.
Young patients with UC tend to have more aggressive disease
and use more immunomodulators, while patients diagnosed
with UC later in life (A3) tend to have a more mild disease
with less need for surgery (20). All current available therapies
for UC have shown equivalent efficacy in children compared to
adults. The apparently higher risk of colorectal cancer in
patients with the onset of UC in childhood almost certainly
reflects the duration of disease. However, concomitant primary
sclerosing cholangitis (PSC) is an important feature in patients
with UC given its increased associated risk for colorectal
cancer.34,48 This influences decisions on surveillance colonos-
copy [Section 2.2).2.4. Use of molecular markers
ECCO statement 2D
No evidence-based recommendation can be made to
implement the routine clinical use of molecular markers
(genetic, serologic) for the classification of UC patients
[EL2, RG C]2.4.1. Serology
A number of (auto)antibodies have been described in
patients with UC, of which the atypical perinuclear anti-
neutrophil cytoplasmatic antibodies (pANCAs) are best
known. Positive pANCA serology is found in approximately
50–60% of patients, although large variability exists due to
differences in methodology.52,53 Overall, pANCA has shown
good accuracy to differentiate CD from UC,54–57 but their
sensitivity is not high enough to justify their use in diagnosis.
These antibodies also lack accuracy in patients with
colitis-yet to be classified, where diagnostic markers
would be of greatest clinical value. A number of other
antimicrobial antibodies as ASCA, OmpC, I2, cBir anti-
flagellin, ALCA, ACCA, are found mainly in patients with
Crohn's disease.58–61
2.4.2. Genotyping
The very active field of IBD genetics has led to the
identification of more than 160 confirmed genetic variants,
which are implicated in a susceptibility to Crohn's disease or
UC. The HLA region is without any doubt the region most
associated with UC,62 but the Interleukin-23 Receptor (IL23R)
gene on chromosome 1,63 the DLG5 gene on chromosome 10,64
the JAK/ STAT pathway, the Multidrug Resistance gene
(MDR)-1 and the Toll like Receptor (TLR) genes have shown
associations with UC.65–73 Recently, a genome wide associa-
tion identifiedmultiple UC susceptibility loci one of which was
at 7q22 and 22q13 (IL17REL).74–76 Since UC is a complex
multifactorial disease, the disease-associated mutations in
these genes will never be sufficient to cause disease, nor will
the absence of mutations be a guarantee of remaining free of
disease. Therefore, testing for these genetic variants is not
recommended for clinical purposes.
Table 3.1 Endoscopic scores for ulcerative colitis commonly used in clinical trials.
Score 0 1 2 3
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3.1. Introduction
Ulcerative colitis (UC) primarily presents in late adolescence
and early adulthood, although the diagnosis may be made at
any age. A small peak in incidence has been demonstrated in
some populations after the fifth decade of life.77 Ulcerative
colitis appears to affect both sexes equally. The inflammation
characteristically commences in the rectum and extends
proximally in a continuous, confluent and concentric manner
to affect a variable extent of the colon, or its entire mucosal
surface. The definitions and classification of the extent of UC
are covered in Sections 1.1 and 2.1 (Table 1.2).16 The proximal
extent of inflammation may progress or regress over time, but
after disease regression the distribution of inflammation tends
to match the extent of previous episodes in the event of
relapse. The view that UC represents continuous colonic
inflammation has, however, been challenged by reports of a
rectal sparing variant and peri-appendicecal patchy inflam-
mation.78 Symptoms depend on the extent and severity of
disease, extra-intestinal manifestations and concurrent ther-
apy. Enteric pathogens may alter the clinical presentation.
3.2. Clinical features and risk factors
3.2.1. Clinical features of ulcerative colitis
ECCO statement 3A
Symptoms of ulcerative colitis are dependent upon extent
and severity of disease, and most commonly include
bloody diarrhoea, rectal bleeding, and/or rectal urgen-
cy. Nocturnal defaecation is also often reported.
Systemic symptoms of malaise, anorexia, or fever are
features of a severe attack [EL5, RG D]
The primary presenting symptom of ulcerative colitis is
visible blood in the stools and is reported by more than 90%of patients. Associated symptoms generally reflect the
endoscopic severity of the disease as a measure of mucosal
damage and may differ according to disease extent.79–89
Loose stools (or a decrease in stool consistency) for more
than six weeks differentiates UC from most infectious
diarrhoea.90 Patients with extensive active UC present with
chronic diarrhoea almost invariably associated with rectal
bleeding, or at least visible blood in the stools. Such
patients also describe rectal urgency, tenesmus, passage of
mucopurulent exudates, nocturnal defaecation and crampy
abdominal pain, or ache over the left iliac fossa prior to and
relieved by defaecation. In contrast, patients with proctitis
usually present with rectal bleeding, urgency, tenesmus,
and occasionally severe constipation.82,84 Anal and minor
perianal lesionsmay complicate severe diarrhoea, but although
simple fistulae may occasionally occur in UC, recurrent or
complex perianal fistulae should always raise the suspicion of
Crohn's colitis.
The onset of UC is usually insidious and symptoms are
often present for weeks or even months before medical
advice is sought. The disease may present with intermittent
episodes of symptoms or as a severe attack (in about 15%)
with systemic symptoms including weight loss, fever and
tachycardia, or even nausea and vomiting.91 Extraintestinal
manifestations, especially an axial or peripheral arthropa-
thy, episcleritis and erythema nodosum may accompany the
presentation in about 10% and rarely precede intestinal
symptoms.92 Thromboembolism is more frequent in UC than
the general population, but is generally associated with active
disease and pancolitis.93
3.2.2. Risk factors for ulcerative colitis
ECCO statement 3B
Appendicectomy for histology proven appendicitis has
been shown to provide some protection against subse-
quently developing UC and in reducing its severity if
performed for ‘true’ appendicitis at a younger age [EL2b,
RGB]
974 A. Dignass et al.The use of non-selective NSAIDs is associated with
increased risk for exacerbating UC [EL2b, RGB]. Short-
term treatment with COX-2 inhibitors is probably safe
[EL1b, RGB]. A family history of CD or UC increases the
risk for developing UC in another family member [EL2b,
RGB]
Active tobacco smoking has a protective effect on the
development and severity of UC.94,95 In contrast, ex-smokers
have about a 70% greater risk of developing the disease,which is
often more extensive and refractory than in those who have
never smoked. Rates of hospital admission and colectomy are
also higher in ex-smokers than in never-smokers.96,97 Improve-
ments in symptoms and a milder course of disease have been
reported in ex-smokers who resume smoking,97,98 but the effect
is inconsistent. Smoking may also prevent the development
of primary sclerosing cholangitis (PSC), or pouchitis after
colectomy and ileal pouch anal anastomosis, but this too has
been challenged.99–101
Cohort studies and meta-analysis have suggested that
appendicectomy performed for true appendicitis at an early
age may be protective against the onset and subsequent
severity of UC. A 69% risk reduction has been reported for
appendicectomy, although a Danish cohort study failed to
confirm this.77,102–106 The protective effect of appendicecto-
my is additional to that of smoking, but does not appear to
protect against the development of PSC.107 When appendi-
cectomy is performed after the onset of ulcerative colitis, the
effect (if any) on the course of the disease is far less clear.
Non-selective non-steroidal anti-inflammatory drugs
(NSAIDs) appear to carry a significant risk of exacerbating
ulcerative colitis. The magnitude of such risk has never been
adequately determined and it is unclear whether all patients
are affected to the same degree.95–98,108–111 In contrast,
preliminary evidence from open-label studies and a double-
blind controlled trial suggest that short-term treatment with
selective COX-2 inhibitors is safe.111,112 Nonetheless, prolonged
usage is best avoided because of potential adverse effects on
other organ systems.
First-degree relatives of patients with UC have a 10–15
fold risk of developing the disease.113 In a population-based
Danish cohort study, the relative risk for developing UC was
10 amongst relatives with the disease.114 In other terms, the
life time risk of UC for a first degree relative is around 2%, or
a 98% chance of not developing the disease, which may help
reassure a parent with UC concerned about the risk to their
children. In familial cases of UC there is a slight female
preponderance and younger age of onset compared to sporadic
cases.113,115
3.3. History, examination and diagnosis
3.3.1. Medical history
ECCO statement 3C
A full medical history should include detailed questioning
about the onset of symptoms, particularly recurrentepisodes of rectal bleeding or bloody diarrhoea, urgency,
tenesmus, abdominal pain, incontinence, nocturnal diar-
rhoea, and features of extra-intestinal manifestations.
Recent travel, food intolerances, contact with enteric
infectious illnesses, medication (including antibiotics and
non-steroidal anti-inflammatory drugs), smoking habit,
sexual practice, family history of IBD, family history of
CRC and previous appendicectomy should be explored
[EL5, RG D]
The diagnosis of UC is suspected from the clinical
symptoms (Section 3.2.1). Infectious or drug-induced forms
of colitis should be excluded. Enquiry should be made into the
family history of both IBD and CRC and patients asked about
possible ocular, oral, joint or skin manifestations.116–121
3.3.2. Examination
ECCO statement 3D
In patients with UC physical examination should include
general well-being, pulse rate, body temperature, blood
pressure, body weight and height, abdominal examina-
tion for distention and tenderness, perianal inspection,
digital rectal examination, oral inspection, and check for
eye, skin and/or joint involvement. Physical examina-
tion may be unremarkable in patients with mild or even
moderate disease [EL5, RG D]
Findings on physical examination depend on the extent
and severity of UC. Examination of patients with mild or
moderate activity is usually unremarkable, apart from
blood on rectal examination. Patients with a severe attack
exhibit fever, tachycardia, weight loss, colonic tenderness,
abdominal distension, or reduced bowel sounds.122
3.3.3. Diagnosis
ECCO statement 3E
A gold standard for the diagnosis of ulcerative colitis is
not available. The diagnosis should be established by a
combination of medical history, clinical evaluation, and
typical endoscopic and histological findings. An infective
cause should be excluded. Where there is doubt about
the diagnosis, endoscopic and histological confirmation
is necessary after an interval [EL5, RG D]
The natural history of UC is characterised by episodes of
relapse and periods of remission, and occasionally by an
unremitting, continuous course (about 5%). A single acute
episode followed by prolonged remission may also occur in
about 5%.35 In the IBSEN study about 60% of patients
experienced a decrease in their symptoms over time.123
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defined in the first three years, and may be characterised
as frequent (≥2 relapses/year) or infrequent (≤1 relapse/
year,32 Sections 1.2 and 2.2.1).
It helps patients to establish the diagnosis, extent and
severity of the disease rapidly, because this influences treat-
ment options and possibly disease progression.89 Since there is
no single pathogenic marker, the diagnosis relies on a com-
bination of medical history, endoscopic findings, histological
features onmultiple colonic biopsies and negative stool tests for
infectious agents. It is unreasonable to expect the histopathol-
ogist alone to make the diagnosis (Section 4), but normal
mucosal biopsies effectively exclude active UC as a cause of
symptoms. In 10% of patients the diagnosis will be changed to
Crohn's disease or the diagnosis of inflammatory bowel disease
discounted during the first 5 years after symptom onset.
Endoscopic and histological confirmation of the diagnosis is
considered essential.124 In a minority of patients it is not
possible to characterise the cause of colitis: see Section 1.1 for
correct usage of the terms ‘IBD Unclassified’ and ‘indetermi-




Initial laboratory investigations should include a full
blood count, serum urea, creatinine, electrolytes, liver
enzymes, iron studies, and C-reactive protein (CRP) [EL5,
RG D]. Faecal calprotectin is an accurate marker of
colonic inflammation. CRP and erythrocyte sedimenta-
tion rate (ESR) are usefulmarkers tomonitor the response
to treatment in severe colitis [EL2b, RGB]. Microbiolog-
ical testing for infectious diarrhoea including Clostridium
difficile toxin is recommended [EL2b, RG B]. Additional
stool tests may be necessary for patients who report a
recent travel abroad [EL5, RG D]. Patient's immunization
status to various viral diseases and tuberculosis status
should be assessed [EL5, RG D]
At diagnosis, every patient should have a full blood count,
inflammatory markers (CRP or ESR), electrolytes and liver
function tests, along with a stool sample for microbiological
testing.122 Faecal calprotectin is an accurate marker of
colonic inflammation. Laboratory markers of chronic inflam-
mation may be normal in mild or moderate distal UC. The
full blood count may reveal thrombocytosis as a result of the
chronic inflammatory response, anaemia indicating disease
severity or chronicity and leucocytosis, raising the possibility
of an infectious complication.
For UC, excluding proctitis, CRP broadly correlates with
clinical activity.39,42,125–127 In patients with severe clinical
activity, an elevated CRP is generally associated with an
elevated ESR, anaemia and hypoalbuminaemia. These have
been used as predictive biomarkers to assess the need forcolectomy in acute severe colitis40,128,129 (Section 5.2.5).
CRP N10 mg/L after a year of extensive colitis, predicted an
increased rate of surgery.126 Neither CRP nor ESR are specific
enough to differentiate UC from infectious or other causes.
The initial diagnosis of UC requires the elimination of
infectious causes of symptomatic colitis. Stool specimens
should be cultured for common pathogens including specific
assays for C. difficile toxin A and B, Campylobacter spp., and
Escherichia coli 0157:H7. Additional tests may be tailored to
the medical history, such as examination of fresh, warm stool
samples for amoebae or other parasites.
3.4.2. Microbial investigations
ECCO statement 3G
In patients with an established diagnosis of UC microbial
testing is recommended in cases of severe or refractory
relapse. This includes testing for C. difficile and
Cytomegalovirus infection EL4, RG C]
It is not routinely recommended to screen for pathogens
such as C. difficile at each flare of the disease, due to
infrequent positive results.130–132 However as C. difficile
infection is a growing health issue in hospitalised UC patients
and is associated both with a higher mortality and resource
utilization, it is advisable to screen hospitalised patients133 as
well as those with a previous history of antibiotic use. In
contrast, microbial stool tests should be performed during a
treatment-refractory or severe relapse.134,135 Flexible sigmoid-
oscopy may be superior to stool C. difficile cytotoxin assay in
patients with pseudomembranous colitis and is appropriate for
patients with diarrhoea where the stool test is negative.136
Reactivation of Cytomegalovirus (CMV) can occur in
ulcerative colitis, particularly (but not invariably) in immuno-
suppressed patients with severe colitis.137–139 The clinical
relevance of this finding remains uncertain, but CMV infection
may cause refractory or severe relapse. The optimal method
for detecting clinically relevant CMV infection in patients with
colitis has not been established. The most commonly used
technique for diagnosis of CMV infection and disease is de-
tection of CMV DNA through PCR. Occasional intranuclear
inclusion bodies consistent with CMV on histopathology do not
necessarily indicate clinically significant infection, but multi-
ple intranuclear inclusions are usually significant.140,141 CMV
should be considered in patients with refractory or severe
colitis and if detected, advice taken from virologists about the
significance and appropriate therapy. Further details can be
reviewed in the ECCO Consesnsus on opportunistic infections
in IBD.13
3.4.3. Biomarkers
The most widely studied serological markers are perinuclear
anti-neutrophil cytoplasmic antibodies (pANCA) and anti-
Saccharomyces cerevisiae antibodies (ASCA). In most series
pANCA are found in up to 65% of patients with UC and in less
than 10% of patients with Crohn's disease. It should be
noted that the incidence of pANCA in UC may depend upon
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In view of the current limited sensitivity of these markers,
their routine use for the diagnosis of UC and for therapeutic
decisions is not clinically justified.
Of the faecalmarkers of intestinal inflammation, neutrophil-
derived proteins such as calprotectin, elastase, lysozyme
and lactoferin, have been evaluated in IBD.144–147 Faecal
calprotectin appears to be the most sensitive, non-invasive
biomarker that reflects intestinal inflammation in established
IBD.148 Recent studies emphasise the value of calprotectin
in selecting patients for diagnostic investigation, assessing,
disease severity (correlating with endoscopic indices), diagnos-
ing relapse and response to treatment.48,49,51,149,150 However,
as with all faecal tests, calprotectin lacks the specificity to
discriminate between types of inflammation. Therefore, its use
as a diagnostic tool in UC is limited, although its value may yet
prove to be a marker with high negative predictive value in
patients with a low likelihood of other pathology.3.4.4. Procedures recommended to establish the diagnosis
ECCO statement 3H
For suspectedUC, colonoscopy, preferablywith ileoscopy,
and segmental biopsies including the rectum are the
preferred procedures to establish the diagnosis and extent
of disease [EL5, RGD]. Patientswith a severe attack should
have abdominal radiography and active disease confirmed
by sigmoidoscopy as a first line procedure [EL5, RGD]
Colonoscopy with intubation of the terminal ileum and
segmental mucosal biopsies are preferred to sigmoidoscopy for
patients with suspected UC. The clinical context and availabil-
ity needs to be considered: colonoscopy and bowel preparation
is best avoided in patients with acute severe colitis to avoid
procedural delays and a higher risk of perforation. Colonoscopy
establishes the diagnosis and disease extent in the majority
of cases. It appears to be more cost-effective than index
sigmoidoscopy.64,151 Deep ulceration at colonoscopy predicts a
worse outcome and higher need for surgery.152
A plain abdominal radiograph is not a diagnostic test for UC,
but is valuable in the initial assessment of patients with
suspected severe UC (Section 3.5.3). Colonic segmental
dilatation exceeding 5 cm with an irregular edge outlined
by gas, correlates strongly with ulceration.153 Persistent
distension in severe UC correlated with poor response
to therapy, higher rate of toxic megacolon and need for
surgery.154 Oesophagogastroduodenoscopy and mucosal
biopsy are recommended in patients with upper gastrointestinal
symptoms. Wireless capsule endoscopy (WCE) represents an
advance in bowel imaging, but large prospective studies are
needed to confirm the diagnostic relevance in ulcerative colitis.
WCE is a potentially useful clinical technique for categorising
those patients with colitis unclassified. Although a normal WCE
does not exclude Crohn's disease, it has a very high negative
predictive value.155 Using WCE, Lopes et al. changed the
diagnosis from IBDU to Crohn's disease in 7/14 patients, though
this did not lead to change in management.1563.5. Assessment of extent, severity and activity
3.5.1. Signs of discontinuous inflammation in ulcerative
colitis-
3.5.1.1. Rectal sparing and caecal patch. Macroscopic and
microscopic rectal sparing has been described in children
presenting with UC prior to treatment.157–160 In adults, a
normal or patchy inflammation in the rectum is more likely to
be due to topical or systemic therapy for UC.161,162 Patchy
inflammation in the caecum is referred to as ‘caecal patch’ and
is observed in patients with left-sided colitis. When there is
macroscopic and histological rectal sparing, or the presence of a
caecal patch in newly diagnosed colitis evaluation of the small
bowel in addition to an ileocolonoscopy is indicated. The nat-
ural history of patients with patchy right colonic inflammation
seems to be similar to those with isolated left-sided UC.141,142
Whenever there is a discontinuous pattern of inflammation in
colitis, a diagnostic work up of the small bowel is indicated to
exclude Crohn's disease in addition to an ileocolonoscopy.
3.5.1.2. Appendiceal skip lesions. Involvement of the
appendix as a skip lesion is reported in up to 75% of patients
with UC.111–113 Appendiceal inflammation has been associated
both with a more responsive course of disease and a higher risk
of pouchitis after ileal pouch anastomosis.163–166 Both findings
require confirmation.
3.5.1.3. Backwash ileitis. Continuous extension of macro-
scopic or histological inflammation from the caecum into the
most distal ileum is defined as ‘backwash ileitis’ (see also
Section 4.2.3). It is observed in up to 20% of patients with
pancolitis. Rarely, ileal erosions may occur in patients without
caecal involvement and this challenges the pathogenic theory
that backwash ileitis is caused simply by reflux of caecal
contents into the ileum.167–169 A more refractory course of
ulcerative colitis has been suggested in those with backwash
ileitis.168 Additional imaging of the small bowel should be
considered in cases of macroscopic backwash ileitis, to differ-
entiate UC from Crohn's disease.
3.5.1.4. Small bowel. Small bowel radiology (by enter-
oclysis, follow-through, CT enteroclysis, MR enteroclysis, or
capsule endoscopy (reviewed in the ECCO Consensus on
diagnosis in Crohn's disease33 and small bowel endoscopy in
inflammatory bowel disease12 is not routinely recommend-
ed. Where there is diagnostic difficulty (rectal sparing,
atypical symptoms, macroscopic backwash ileitis) then a
diagnostic workup to exclude Crohn's disease in addition to
an ileocolonoscopy is warranted.
3.5.2. Activity indices in ulcerative colitis
ECCO statement 3I
Instruments for measuring clinical and/or endoscopic
disease activity in UC are available, but none has been
subjected to an adequate validation process. In daily
routine such indices are barely used. The incorporation of
a simple clinical and/or endoscopic scoring system is
desirable, intended to improve care of UC patients and to
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admission to hospital is warranted for all patients fulfilling
Truelove and Witts' criteria for severe colitis to prevent
delayed decision-making which may lead to increased
perioperative morbidity and mortality [EL4, RGD]
At present, the use of disease activity scores for UC is
limited to clinical studies. However, based on the need to
standardise documentation of IBD patients on a European
level, the incorporation of a simple, valid clinical and/or
endoscopic scoring system in electronic patient files is
warranted. The original classification of severe UC was
proposed by Truelove and Witts in 195520 and has stood the
test of time, because it is easy to remember and apply. This
classification is still considered to the Gold Standard for rapid
identification of outpatients in need of immediate admission
to hospital and intensive treatment.153,170
3.5.3. Investigations for acute severe colitis on admission
Patients should have their full blood count, inflammatory
markers (C-reactive protein, or ESR), electrolytes and liver
function tests measured, along with a stool sample for culture
and assay for C. difficile toxin.170
A plain abdominal radiograph should be performed, not only
to exclude colonic dilatation (≥5.0 cm) but also to estimate
the extent of disease and look for features that predict
response to treatment. The proximal extent of disease broadly
correlates with the distal distribution of faecal residue; in 51
episodes of severe colitis, this guide overestimated the extent
in 18% and underestimated it in 8%.128 The presence of mucosal
islands (small, circular opacities representing residual mucosa
isolated by surrounding ulceration), or more than two gas-filled
loops of small bowel on the radiograph are associated with a
poor response to treatment.171,172
A flexible sigmoidoscopy should confirm the diagnosis of
severe colitis and help exclude infection, particularly with
cytomegalovirus.137,138,173 If it is strongly suspected that
CMV might be responsible for deterioration (such as a patient
on immunomodulators in association with a high fever), it is
appropriate to request urgent histopathology. An answer can
be available within 4 h. Phosphate enema preparation before
flexible sigmoidoscopy is considered safe, but is probably best
avoided in patients with a dilated colon. Full colonoscopy in
patients with acute severe colitis is not recommended, since
purgative preparation can provoke dilatation and colonic per-
foration is a real hazard of colonoscopy during active disease.
Endoscopic criteria for severe colitis include a haemorrhagic
mucosawith deep ulceration,mucosal detachment on the edge
of these ulcerations and well-like ulceration,152,174 all of which
can be assessed at flexible sigmoidoscopy.
3.5.4. Reassessment of extent and severity of ulcerative
colitis
ECCO statement 3J
Findings at endoscopy for patients with UC in remission
are predictive of outcome [EL2, RGB]. Endoscopicreassessment is appropriate at a relapse, or for steroid-
dependent or -refractory UC or when considering
colectomy [EL5, RGD]
Despite the importance of disease location in determining
the prognosis, the risk of cancer and the choice of therapy,
the appropriateness of periodic restaging after index
colonoscopy has never been studied. In a Norwegian
population-based cohort study, mucosal healing after a
year of treatment was associated with a low risk of future
colectomy (1.6% of the patients with mucosal healing,
compared to 7% without mucosal healing).175 40% patients
who achieved endoscopic remission (defined as a lack of
significant inflammation at endoscopy and on rectal biopsy)
remained asymptomatic during a year of follow-up in
contrast with 18% of patients who did not achieve it.176 In
a prospective multicenter study 78 patients with active,
mild-to-moderate UC received oral and rectal mesalamine
those in clinical remission with less severe endoscopic scores
(defined as normal-looking mucosa, with only mild redness
and/or friability), were less likely to relapse at 1 year than
patients solely in clinical remission.177
Colonoscopy is more sensitive than barium studies for
estimating disease extent, but the risk of malignancy is
historically based on contrast studies and colonoscopy
defines a different extent to histopathology.78,178–180
Chromoendoscopy better correlates with the disease
extent determined by histopathology, but the procedure
is time-consuming and requires a level of expertise not
universally available.181 Drug-induced clinical remission
may not be associated with endoscopic or histological
remission, but the prognostic implications of endoscopic
re-evaluation in quiescent disease have yet to be deter-
mined.78 The area calls for systematic study.
3.6. Endoscopy, ultrasound and colonography
3.6.1. Endoscopic features of ulcerative colitis
ECCO statement 3K
No endoscopic feature is specific for UC. The most
useful endoscopic features of UC are considered to be
continuous and confluent colonic involvement with
clear demarcation of inflammation and rectal involve-
ment. [EL2b, RGB Endoscopic severity of UC may be
best reflected by the presence of mucosal friability,
spontaneous bleeding and deep ulcerations [EL2b,
RGB]
Endoscopic changes characteristically commence proxi-
mal to the anal verge and extend proximally in a continuous,
confluent and concentric fashion. The demarcation between
inflamed and normal areas is usually clear and may occur
abruptly within millimetres, especially in distal disease.
Wide variation in endoscopic interpretation of disease
activity is well recognised.182 Although granularity, vascular
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to predict global assessment of endoscopic severity,183 the
Ulcerative Colitis Endoscopic Index of Severity (UCEIS) uses
vascular pattern, bleeding and ulceration, each with 3 or 4
levels of severity, to capture the complete range of endoscopic
severity and 88% of the variance between endoscopists
(Table 3.2).184 It is the first validated endoscopic index of
severity in UC.
The endoscopic features of mild inflammation are erythe-
ma, vascular congestion of the mucosa and loss of visible
vascular pattern. Moderately active colitis is characterised by
complete loss of vascular pattern, blood adherent to the
surface of the mucosa and erosions, often with a coarse
granular appearance and mucosal friability (bleeding to light
touch). Severe colitis is characterised by spontaneous bleed-
ing and ulceration (Table 3.1).78,180,182,184,185 The choice of
endoscopic score is complex and has been reviewed.23,182,186
In contrast to Crohn's disease, ulcers in severe UC are always
embedded in inflamed mucosa. The presence of deep
ulceration is a poor prognostic sign.180 In longstanding disease,
mucosal atrophy can result in loss of haustral folds, luminal
narrowing and post-inflammatory (‘pseudo’) polyps. The
meaning of ‘mucosal healing’ in UC has been the subject of
detailed review.187
The total score is the sum of all three descriptors in the
worst affected area of the colon visible at sigmoidoscopy.
Although the original version of the UCEIS182 gave a score of
1 to the normal appearance of a descriptor, a decision was
made to change the numbering of the levels, with normality
awarded a score of 0, so that the simple sum of the UCEIS
ranges from 0 to 8.1843.6.2. Abdominal ultrasound and scintigraphy in ulcerative
colitis
ECCO statement 3L
Trans-abdominal ultrasound is helpful in monitoring
disease activity and extent as well as treatment
success [EL3, RGC]
Abdominal ultrasound can be used to screen for small
bowel or colonic inflammation with a sensitivity of 80–90%.
Ultrasound has the advantage of being low cost, easy to
perform without prior preparation and non-invasive, but the
accuracy is very much dependent on the skill of the operator
and there is low specificity for differentiating UC from other
causes of colonic inflammation.24,188–191 However, abdom-
inal ultrasound appears to be helpful in monitoring treat-
ment success and there is initial data that ultrasound might
help to predict the course of the disease.192
Hydrocolonic ultrasound (abdominal ultrasonography in
conjunction with retrograde instillation of water in the
colon) has a high sensitivity for identifying active colitis, but
the method is too cumbersome for day to day clinical
practice.193 Doppler ultrasound of the superior and inferior
mesenteric arteries has been used to evaluate disease
activity and risk of relapse. It should be considered as acomplementary technique for assessing disease activity in
expert hands.194,195 For this method to be viable, further
prospective, multi-centre studies are needed.
Leukocyte scintigraphy is safe, non-invasive and poten-
tially allows assessment of the presence, extent and activity
of inflammation. However the method lacks specifici-
ty196,197 and can therefore currently not be recommended
as a standard diagnostic tool for ulcerative colitis. It is
unreliable if patients are taking steroids. Novel markers to
detect intestinal inflammation which are not associated with
exposure to radiation are being developed.3.6.3. Virtual colonography in ulcerative colitis
ECCO statement 3M
Virtual colonography is an evolving technology. The
limited data currently available do not demonstrate a
diagnostic value for assessing the disease extent in
patients with suspected or proven UC EL4, RGCFew studies on a limited number of patients have investi-
gated MR-colonography or CT-colonography in UC. The results
are conflicting and subtle changes of the mucosa such as
erosions or flat polyps are insufficiently visualised.198,199
Because of these limitations, virtual colonoscopy is no
alternative to standard colonoscopy in patients with UC at
present.3.7. Colonic stenosis in ulcerative colitis
ECCO statement 3N
Each colonic stenosis in UC should raise the suspicion of
colorectal carcinoma. Multiple biopsies should be
taken and a surgical option should be sought. When
endoscopic intubation of the colon is not possible,
imaging procedures, such as double contrast barium
enema, CT and/or MRI colonography may be employed
[EL5, RGD]In long standing ulcerative colitis, a colonic stricture signals
an increased risk for colorectal carcinoma and requires careful
histological assessment.37 If colonoscopy is incomplete due
to stricture a double or even single contrast barium enema
can be used to assess the stricture and proximal colon.200
However CT colonography can assess the mucosal pattern
proximal to a stricture, as well as extra-intestinal pathology
and is therefore becoming the investigation of choice in this
situation.201






Vascular pattern Normal (0) Normal vascular pattern with arborisation of capillaries clearly defined,
or with blurring or patchy loss of capillary margins
Patchy obliteration (1) Patchy obliteration of vascular pattern
Obliterated (2) Complete obliteration of vascular pattern
Bleeding None (0) No visible blood
Mucosal (1) Some spots or streaks of coagulated blood on the surface of the mucosa
ahead of the scope, which can be washed away
Luminal mild (2) Some free liquid blood in the lumen
Luminal moderate
or severe (3)
Frank blood in the lumen ahead of endoscope or visible oozing from mucosa
after washing intra-luminal blood, or visible oozing from a
haemorrhagic mucosa
Erosions & Ulcers None (0) Normal mucosa, no visible erosions or ulcers
Erosions (1) Tiny (≤5 mm) defects in the mucosa, of a white or yellow colour with
a flat edge
Superficial ulcer (2) Larger (N5 mm) defects in the mucosa, which are discrete fibrin-covered
ulcers when compared to erosions, but remain superficial
Deep ulcer (3) Deeper excavated defects in the mucosa, with a slightly raised edge
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4.1. General
In ulcerative colitis, histopathology is used for diagnosis,
the assessment of disease activity and the identification
of intraepithelial neoplasia (dysplasia). The latter will be
addressed separately.
4.1.1. Considerations
Several factors have influenced the accuracy of the histopath-
ological diagnosis of UC, as it has in Crohn's disease. The use of
colonoscopy as the diagnostic procedure of choice has allowed
the analysis of multiple biopsies from different segments of
the colon. More biopsies are obtained, often early in the
evolution of the disease. Furthermore, biopsies can be
obtained in young children presenting with bloody diar-
rhoea. In addition, the introduction of new therapies
inducing mucosal healing has made the pathologists aware
of the impact of treatment upon the microscopic features.
This has changed the approach to histopathological diag-
nosis in the past decade.
4.1.2. Evaluation of the literature
Articles reporting original research into the reproducibility,
sensitivity, specificity and predictive value of individual
features useful for the histopathological diagnosis of ulcera-
tive colitis were sought from the literature, using Medline and
PubMed. Only those features which achieved moderate
reproducibility judged by the kappa statistic, or findings
confirmed by several studies were considered. In addition, we
have reviewed studies describing and defining diagnostic
microscopic features. The literature can be divided into
groups depending upon the number (one, or multiple) of
biopsies examined or the duration of the disease. In ten
studies multiple biopsies were examined (including two
comparing the diagnostic value of both single and multiplebiopsies).159,202–210 The literature on the duration of the
disease can also be divided. The first group is composed of
studies with biopsies obtained in patients with an established
diagnosis of ulcerative colitis, based on extended clinical
follow-up. Disease duration varies between 6±3 weeks and
12 years. A second group is composed of retrospective studies
without clear data on the duration of the disease. These
papers can be pooled with the first group, because the
diagnosis is again established through a period of follow up. A
third group applies to studies on biopsies obtained early after
onset of the disease, before treatment.157,159,208,209,211 For
early onset disease, the duration of disease varies between 4
and 14 days (3.69±0.52 days after the appearance of rectal
bleeding, or 10 days after initial symptoms).203,211,212 In these
studies, the diagnoses was subsequently confirmed by follow-
up of the patients and are prospective studies. Children are
mainly included in the third group.
Whilst it may seem self-evident to experienced clinicians,
care should be taken to avoid confusing the use of histopa-
thology to confirm a diagnosis of UC and histopathology for
confirming the presence of active disease. This is particularly
relevant to clinical trials of active UC (Section 4.4).4.2. Microscopic features—definitions
A large number of microscopic features have been evaluated.
They can be broadly classified into• architectural features
• epithelial abnormalities, and
• inflammatory features.
Architectural features include crypt branching, crypt distor-
tion, crypt atrophy and surface irregularity. Epithelial cell
abnormalities are mucin depletion and Paneth cell metaplasia.
Inflammatory features include increased lamina propria
980 A. Dignass et al.cellularity, basal plasmacytosis, basal lymphoid aggregates,
lamina propria eosinophils.
4.2.1. Crypt architectural abnormalities
Crypt branching: two or more branched (bifurcated) crypts
in a well oriented section, whether the branching is in the
vertical or horizontal axis.208,211,213–215 When applied to a
single crypt, the feature is less specific.214 The pathogenesis
can be accounted for by regeneration following previous
damage or destruction (cryptolysis).
Mucosal (crypt) distortion: irregularities in crypt size
(i.e. variable diameter), spacing, orientation (i.e. loss of
parallelism), or shape (including branching with a cystic
configuration).159,203–205,208,209,211,215 In some studies this
includes separation from the underlying muscularis muco-
sae.204,211 Samples from the anal transition zone or columnar
cuff (sometimes wrongly termed “low rectal biopsies”) are not
suitable for the assessment of crypt branching or mucosal
distortion.
Mucosal (crypt) atrophy and crypt density: a combination
of crypt depletion (thinned-out crypts, generally recognised
by a distance of more than one crypt diameter between
crypts) and an increase in the distance between the
muscularis mucosae and the base of the crypts.211,215,216
Some authors emphasise either crypt depletion203 or an
increased distance between the muscularis mucosae and the
base of the crypts208 rather than both features. An increase
in the intercryptal space and the crypt–muscularis mucosae
distance may be normal in the caecum and distal rectum.215
The distance between the muscularis mucosae and the crypt
base should not be evaluated in the vicinity of lymphoid
follicles. The pathogenesis can be explained as a conse-
quence of crypt death from disease and has been studied in
experimental animal models. If all crypt cells die, crypts
cannot regenerate and disappear within 48 h. However, if one
or more clonogenic cell survives the insult, rapid proliferation
regenerates the crypt within 72–96 h. The mucosa subse-
quently heals by clonal expansion and the number of crypts
that survive to regenerate following a cytotoxic insult
correlates with symptom severity. A number of growth factors
affect crypt regeneration in these murine models.217 Never-
theless, it remains unclear what size of (uncrushed) biopsy is
adequate for proper evaluation and how many levels of the
biopsy need to be examined properly to evaluate atrophy.
Surface irregularity: Surface irregularity (synonyms in-
clude villous surface, villiform surface, or villous muco-
sa)203,214 means wide crypt mouths, giving the mucosal
surface a finger-like appearance.211 The impression is due to
separation of crypts216 and a semantic distinction between
“irregular surface” and “villous surface” has been proposed,
according to the villous-crypt ratio.204
4.2.2. Epithelial cell abnormalities
Paneth cell metaplasia: Paneth cells are normally ex-
tremely uncommon in the colon distal to the splenic
flexure, being present in 0–1.9% of non-IBD controls.218
The presence of Paneth cells in the distal colon can be
termed Paneth cell metaplasia. The pathogenesis is related
to epithelial regeneration and repair.218
Mucin depletion: defined as a reduction in number of goblet
cells or depleted mucin within cells.2154.2.3. Inflammatory features
Basal plasmacytosis: defined either as the presence of plasma
cells around (deep 1/5th of the lamina propria) or below the
crypts, alongside or penetrating the muscularis mucosae.
Basal plasmacytosis is also referred to as subcryptal plasma
cells,203 plasmacytosis with extension in the base of the
mucosa,159 or accumulation of plasma cells between the base
of the crypts and the muscularis mucosae.208 The abnormality
can be focal or diffuse and subcryptal location of the cells is not
always present.203,211
Lamina propria cellularity: evaluated according to density,
composition and distribution. An increase in the total number
of plasma cells, lymphocytes, histiocytes and eosinophils is a
feature of all types of colorectal inflammation215 and is of
limited discriminant value. In UC the cellular infiltrate is
diffuse and transmucosal.
Increased density has been described as “a subjectively
abnormal” infiltrate,214 a “prominent” increase (assessed by
widening of the intercryptal space by the inflammatory
infiltrate216 or simple “hypercellularity”.203 The increase is
difficult to quantify. Increased lamina propria cellularity may
also be absent in quiescent disease, following treatment, or in
the natural course of the disease.181,219 Furthermore, increased
lamina propria cellularity may persist in infective colitis220 and
is a normal feature of caecal biopsies.
The composition has been examined to resolve these
dilemmas. Some authors discriminate between an increase in
neutrophils alone and an increase in both round cells and
neutrophils. Neutrophilsmay be present in the lamina propria or
between epithelial cells, are readily recognised and a repro-
ducible feature of inflammation.216 More than three neutrophils
in the lamina propria outside capillaries may be abnormal,204
but the exact number has not been agreed. Neutrophils are a
feature of cryptitis with migration of neutrophils through the
crypt epithelium, inducing crypt disruption and crypt abscesses,
which may be responsible for cell surface damage or disruption.
The diagnostic value of neutrophils in UC, however, is limited
because they are also present in infective colitis and other
forms of colitis.216,203 In contrast, eosinophils in the lamina
propria are highly variable. An increase has been noted in UC
and a potential diagnostic value has been proposed, but data
were obtained from studies of longstanding disease.205,213
The distribution of the lamina propria cellular inflammatory
infiltrate has been divided into: focal (normal background
cellularity with areas of increased cellularity); patchy (abnor-
mal background cellularity with variable intensity); and diffuse
(abnormal background cellularity with an overall increase in
density). These terms are preferred. Confusion is caused when
the term “discontinuous” is used to describe both focal and
patchy changes in some studies,215 or used as a synonym for
focal in others.205 A diffuse increase can be either superficial
(confined to the superficial and middle thirds of the lamina
propria) or transmucosal (usually maximal in the lower third).
The distribution can be evaluated in a single sample or between
multiple samples from the same site. To avoid diagnostic error,
the criteria of diffuse transmucosal inflammation for diagnosing
ulcerative colitis should be avoided in biopsies from early onset
disease in children,159 or after treatment and when disease is
resolving or quiescent. In these circumstances the biopsy may
be normal or show focal changes.161,207,221
Basal lymphoid aggregates: nodular collections of lympho-
cytes between the crypt base and muscularis mucosae,214
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gates are needed for this feature to be considered
abnormal.204,215,216
Stromal changes: diffuse thickening of the muscularis
mucosae or a double muscularis mucosae (which is unusual,
but characteristic when present) have been observed in
longstanding active and quiescent UC.223
Backwash ileitis: ileal inflammation in UC is called
backwash ileitis, despite the fact that the backwash or reflux
pathogenesis has never been established. ‘Backwash ileitis’
should be in continuity with colonic inflammation (see also
3.5.1) and the lesions in the caecum should show a similar, or
greater degree of active inflammation. The ileal lesions in
‘backwash ileitis’ are characterised by active inflammation in
the villi and lamina propria, together with shortening and
blunting of the villi. Focal, isolated ileal erosions, mucous
gland metaplasia or patchy oedema with mild active inflam-
mation are features suggestive of Crohn's disease.167,169
ECCO statement 4A
For a reliable diagnosis of ulcerative colitis multiple
biopsies from five sites around the colon (including the
rectum) and the ileum should be obtained. Multiple
implies a minimum of two samples [EL1b, RGB]
ECCO statement 4B
Biopsies should be accompanied by clinical information
including the age of the patient, duration of disease and
duration and type of treatment [EL1b, R GB]. Biopsies
from different regions should be handled in such a way
that the region of origin can be identified [EL1c RGA]. This
can be done by using different containers, multiwell
cassettes, or an acetate strip [EL5, RG D]. All tissue
samples should be fixed immediately by immersion in
buffered formalin or an equivalent solution prior to
transport. It is recommended that multiple sections from
each sample are examined [EL5, RGD]
4.3. Microscopic features—appraisal of the diagnosis
4.3.1. Early stage disease
It has been proposed that a non-specific increase in the
inflammatory infiltrate in the lamina propria in combination
with absent crypt architectural distortion, indicates a diagnosis
of acute, infective colitis203,216 rather than UC. This finding,
however, is not confirmed in those studies of patients with early
onset colitis (within 10 days of symptoms).212,224
ECCO statement 4C
Basal plasmacytosis at the initial onset has a high
predictive value for the diagnosis of IBD [EL 3, RG C]Repeat biopsies after an interval may help to solve
differential diagnostic problems and establish a defin-
itive diagnosis especially in adults, by showing addi-
tional features [EL 5, RG D]
Basal plasmacytosis is observed in biopsies obtained at
early onset in 38–100% of adult patients203,211 and can help
differentiate between UC and infectious colitis.211 It is
particularly a feature in young children; in these cases it is
notably present in rectal biopsies and decreases proximal-
ly. It is an early feature, sometimes the first lesion to
appear159,203,208,209,211 and a good predictive marker.
Glandular abnormalities can be identified with good
(83-90%) interobserver agreement.204,222,225 According to most
studies, diffuse crypt architectural irregularity and reduced
crypt numbers or atrophy indicate UC.213,215 Nevertheless,
these featuresmay still not be present in biopsies obtained from
patients with colitis at an early stage.211 Crypt architectural
changes were observed in biopsies obtained between 16 and
30 days after onset,211 but not in earlier biopsies. In another
study203 abnormal architecture was found in all biopsies
obtained within days of onset, but in this study disease onset
was defined by loss of blood and not by other symptoms. Crypt
distortion and mucosal atrophy may return to normal or remain
unchanged after resolution of symptoms.161,221
ECCO statement 4D
In young children or patients with an aberrant presenta-
tion of colitis, UC should always be considered in the
differential diagnosis even if the pathology is not typical
[EL1b RG B]
Reliable diagnostic features may be absent from biopsies
obtained in early onset disease, in acute severe colitis, or in
patients with an atypical immunological response (such as
young children, or patients with primary sclerosing cholangitis).
The routine use of additional techniques such as immunohisto-
chemistry is not recommended at present.
4.3.2. Established disease
ECCO statement 4E
A diagnosis of established ulcerative colitis is based upon
the combination of: basal plasmacytosis (defined as
presence of plasma cells around (deep part of the lamina
propria) or below the crypts (subcryptal)), heavy, diffuse
transmucosal lamina propria cell increase and widespread
mucosal or crypt architectural distortion [EL 1a, RG A]
The exact number of features needed for diagnosis has
not been established. A correct diagnosis of UC is reached in
approximately 75% of the cases when two or three of the
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decreased crypt density, irregular surface and heavy diffuse
transmucosal inflammation are present, in the absence of
genuine granulomas.204,209
ECCO statement 4F
Widespread mucosal or crypt architectural distortion,
mucosal atrophy and a villous or irregular mucosal
surface appear later during the evolution of the disease
(4 weeks or more). They suggest a diagnosis of ulcerative
colitis in established disease [EL 2, RG B]
In established UC a villous surface is present in 17–63 % of
the cases (compared to 0-24% for Crohn's disease and 0-7% for
infective colitis).215 The lesion is observed in approximately
one third of the initial biopsies of children with ulcerative
colitis.208 In adults this feature was present in approximately
23% of the patients presenting 16–30 days after the initial
symptoms, but not in earlier biopsies.211
ECCO statement 4G
Basal plasmacytosis is a good diagnostic feature in
established ulcerative colitis [EL 2, RG B]. A heavy,
diffuse transmucosal lamina propria cell increase is a
good diagnostic feature in established active disease
[EL 2, RG B]. Distribution of inflammation along the
colon, with a decreasing gradient of inflammation from
distal to proximal is in favour of a diagnosis of ulcerative
colitis in an untreated patient [EL5 RG D]
The diagnostic value of basal plasmacytosis is confirmed by
studies of biopsies obtained in established disease, being
present in up to 63% of cases.204 The feature is rare in
non-IBD colitis,214 but it is also common in Crohn's disease. Basal
plasmacytosis decreases and can disappear during treatment.
A heavy, diffuse, transmucosal, lamina propria cell infil-
trate favours a diagnosis of UC,215 but patchy inflammation213
can occasionally be seen in ulcerative colitis or, when multiple
biopsies are examined, a single piece may have evidence of
chronic colitis and others have normal mucosa.208,221,226 The
heavy, diffuse transmucosal lamina propria cell increase can
be absent in young children (b12 years). It can decrease in
intensity and become patchy during the natural evolution of the
disease or subsequent to treatment. This feature is therefore
mainly useful for the diagnosis in established disease. Its
absence does not exclude a diagnosis of UC.
ECCO statement 4H
General or widespread crypt epithelial neutrophils
(cryptitis and crypt abscesses) favour ulcerative colitisHowever these lesions may occur in infections and
other types of colitis [EL 2b, RG B]. Lamina propria and
intraepithelial neutrophils are absent in inactive or
quiescent disease. [EL 2b, RG B]
General or widespread crypt epithelial neutrophils favour
a diagnosis of ulcerative colitis, but crypt abscesses and
cryptitis can also occur in infective colitis, although they are
less prominent.26 Neutrophils are absent during inactive or
quiescent disease.
Basal lymphoid aggregates favour a diagnosis of established
UC, but may occur in Crohn's colitis214,216 and are not useful in
early onset disease.
ECCO statement 4I
Paneth cellmetaplasia distal to the splenic flexure is a non
specific feature. It is suggestive of a diagnosis of ulcerative
colitis in established disease [EL 3, RG C]. Severe,
widespread mucin depletion is helpful for the diagno-
sis of ulcerative colitis in active disease [EL 3, RG C]
Paneth cell metaplasia favours a diagnosis of ulcerative
colitis.205 The predictive value is high but the sensitivity is
low.214 It is not seen in biopsies obtained early in the
disease211,216 and appears to be related to established
disease.218 Mucin depletion also favours a diagnosis of
ulcerative colitis. It correlates with disease activity, so is a
helpful, but not pivotal diagnostic feature.159 Mucin preser-
vation in association with active disease, however, may favour
a diagnosis of Crohn's disease rather than UC.206
4.4. Microscopic features—disease activity
ECCO statement 4J
The pathology report should give an indication of the
activity of the disease [EL5 RG D]
Disappearance of mucosal inflammation following treat-
ment has been observed,161 so biopsies are also used for
distinguishing between quiescent and active disease, as well
as different grades of activity. Scoring systems have been
introduced for the assessment of disease activity, particularly
for therapeutic trials. The potential value of histopathology
for predicting relapse and evaluating adequate control of
inflammation has implications for therapeutic management
and reducing the risk of neoplasia. Both epithelial damage in
association with neutrophils and basal plasmacytosis have been
proposed as markers of disease activity and the prediction of
relapse.36,227–229
The value of histopathology as independent confirmation
of disease activity in clinical trials for the treatment of mild-
or moderately active UC is frequently overlooked. A lack of
9832nd European evidence-based consensus on the diagnosis/management of ulcerative colitis.microscopic inflammation on a mucosal biopsy effectively
excludes active UC and this is an important measure for
validating active disease when recruiting patients to clinical
trials, since it can be assessed independently from endosco-
py. The problem is prevalent: in one Phase 3 trial of a new
agent for treating mild-moderately active UC, 77/511 (15%)
patients had inactive UC at study entry, despite clinical and
endoscopic criteria indicating active disease, they were
excluded.230 This clearly raises complex issues. There are
logistic constraints on the time to histological analysis,
especially by a central reader, that effectively prevent it
being used as an inclusion criterion, other than to exclude in
retrospect those patients with inactive disease. Neverthe-
less, the European Medicines' Agency in their guidelines to
clinical trials of new agents for UC state that the absence of
histological evidence of active inflammation effectively
excludes active disease (CHMP/EWG/ 18463/2006, adopted
28 Jan 2008).
ECCO statement 4K
The term indeterminate colitis (IC) should be restrict-
ed to resection specimens. When patients have colitis
that has yet to be classified after all clinical, radiologic,
endoscopic and histological results are taken into ac-
count, then the preferable term is IBD unclassified (IBDU)
[EL5 RG D]
4.5. Conclusions
The evolution of the microscopic features that are useful for a
diagnosis of ulcerative colitis is a time- and disease-activity
dependent process. This notion is confirmed by experimental
studies. In early onset disease, few or no characteristic
features may be present. In established disease the diagnosis
can be based upon a combination of basal plasmacytosis, crypt
architectural abnormalities, diffuse transmucosal inflamma-
tory infiltrate and epithelial surface irregularity. The natural
evolution from active to quiescent disease and treatment also
has an impact on microscopic features. In quiescent disease,
few features may persist, neutrophils are notably absent and
biopsies may be normal.
It appears important to distinguish between different
situations for the diagnosis of ulcerative colitis:
• Biopsies obtained during the initial phase of the disease
(within two weeks of onset of symptoms, including young
children and without treatment)
• Biopsies obtained from patients with established disease
before treatment (symptoms for more than 4–6 weeks)
• Biopsies obtained from patients with established disease
after treatment (examination of previous biopsies is
desirable)
In every patient, including children, the diagnostic yield
can be increased when multiple biopsies from different
segments of the colon are examined, including the rectumand the ileum, although these should be carefully labelled
for proper assessment.209,210,231,232
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